

B³

12. The chimeric protein of Claim 11 in which the heterologous polypeptide is an epitope tag.

Remarks

The above Amendments and these Remarks are in reply to the Office action mailed March 28, 2001. Applicant will address the Examiner's Remarks in the order presented in the Office action.

Claim Rejections 35 U.S.C. §112

Claims 8-12 stand rejected under §112, second paragraph as being indefinite for failing to particularly point out and distinctly claim the subject matter which Applicant regards as the invention. Specifically, the Examiner has rejected claim 8 because the Examiner feels that it is unclear what Applicant intends by "intermediate SH2 domain." Additionally, the Examiner has requested that "SH2" be defined. Applicant submits that this term is well understood in the art and refers to "src homologs." Indeed, in the Felder et al reference, cited by the Examiner, the first sentence provides this definition of SH2 domain, and thus supports Applicant's contention that it is well known in the art. Applicant also refers the Examiner to page 5, line 23-28 of Applicant's specification. Here the Examiner will note that Applicant defines what is meant by "intermediate SH2 domain," which is "...the region between the two SH2 domains..." The Examiner will note that Applicant referred to "intermediate" as "inter." Clearly, Applicant intended "inter" to be "intermediate." Accordingly, Applicant has amended the specification.

Thus, Applicant respectfully submits that a skilled practitioner of this art would know what Applicant intends when Applicant refers to "intermediate SH2 domain."

The Examiner will further note that Applicant has amended claim 8 to refer to the amino acid sequences that are shown in SEQ ID Nos. 1 and 2.

Claim 9 stands rejected because of the term "bromodomain." The Examiner has stated that this term is not defined by the claim, and renders the claim indefinite. The Examiner will note that claim 9 has been amended to recite the amino acid sequence that comprises the bromodomain, as pointed out by the Examiner. Further, the Examiner will recall that claim 9 depends from claim 8, and thus now includes the amino acid sequences claimed in claim 8.

The Examiner has rejected claim 12 because of the terms "Glu tag" and "myc epitope tag." The Examiner will note that these terms have been amended out of the claims, and thus the rejection is obviated.

Claim 11 stands rejected because it depends upon an indefinite base claim. The Examiner will note that the base claim has been amended to refer to SEQ ID numbers, and references to the figures have been deleted.

35 U.S.C. §112 Rejections

The Examiner has stated that claims 8 and 9 stand rejected under §112, first paragraph, because the specification does not provide enablement for any phosphatidylinositol-3' kinase associated proteins that binds to the intermediate SH2 domain on a regulatory subunit of phosphatidylinositol-3' kinase. The Examiner will note that Applicant has obviated the rejection by amending claim 8, from which claim 9

depends to refer to SEQ ID No. 2 or SEQ ID No. 1. Thus, Applicant believes that the rejection is obviated.

35 U.S.C. §102 Claim Rejections


Claim 9 stands rejected under §102(b) as being anticipated by Felder et al. The Examiner will note that, as now amended, claim 9 is not anticipated by Felder et al. No where does Felder et al. show the sequences claimed by the Applicant, nor does that reference present a bromodomain, as reflected in Applicant's claim 9.

In view of the above Amendments and Remarks, reconsideration of the pending claims is requested.

The Commissioner is authorized to charge any fees associated with this communication to Deposit Account No. 15-0615 for any matter in connection with this response, including any fee for extension of time which may be required. A duplicate copy of this authorization is enclosed.

Respectfully submitted,

Date: September 28, 2001

By: 
Gregory Giotta
Reg. No. 32,028

ONYX Pharmaceuticals, Inc.
3031 Research Drive
Richmond, California 94806
Telephone (510) 262-8710
Facsimile (510) 222-9758

APPENDIX A

Amendments showing modifications:

Please amend the specification as follows:

Page 5, line 25, delete "inter" and substitute --intermediate-- therefor.

Please amend the claims as follows:

8. An isolated phosphatidylinositol-3' kinase associated protein(s) encoded an amino acid sequence comprising SEQ ID No. 2 or SEQ ID No. 1, and that bind to the intermediate SH2 domain on the regulatory subunit of phosphatidylinositol-3' kinase by the associated protein(s) C-terminal amino acids.
9. An isolated phosphatidylinositol-3' kinase associated protein(s) of claim 8 which further comprises a bromodomain comprising amino acids 151-313 or SEQ ID No. 2.
10. An isolated phosphatidylinositol-3' kinase associated protein(s) of claim 9 comprising the amino acid sequence shown in [FIG. 2] SEQ ID No. 2, or the amino acid sequence encoded by the cDNA shown in [Fig. 1] SEQ ID No. 1.
12. The chimeric protein of Claim 11 in which the heterologous polypeptide is [a Glu tag or a myc] an epitope tag.